Language
Austria

Available again · 14.09.2026

Supply shortage Austria: Diclofenac Sandoz retard 100 mg - Filmtabletten

Affected country: Austria · Reported period: 29.05.2026 – 10.09.2026 · Active ingredient: DICLOFENAC NATRIUM

CountryAustria
PZN0792550, 0792544
ENRBASG-ID 461f32d5b4c95a565e784d5a24e52f4f22899d25; Zulassungsnummer 1-17997
Notification typeAvailable again
Start29.05.2026
Expected end10.09.2026
Last update14.09.2026
ReasonManufacturing capacity constraints
ATCM01AB05
Hospital-relevantNo

Notice context

A supply shortage has been recorded for Diclofenac Sandoz retard 100 mg - Filmtabletten in Austria. The stated reason is “Manufacturing capacity constraints”. The notice concerns the active ingredient DICLOFENAC NATRIUM and is not identified as hospital-relevant.

This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.

Primary source: BASG – Medikamente Info Austria

Official shortage notice for Austria. Responsibility and update procedures follow the information supplied by the relevant authority.

Check the official notice list →

Implications for procurement and the supply chain

The notice for Diclofenac Sandoz retard 100 mg - Filmtabletten is a supply signal concerning DICLOFENAC NATRIUM in Austria. The published reason “Manufacturing capacity constraints” determines which data should be verified first.

For manufacturing or capacity constraints, the focus is on credible restart dates, available batches, qualified sources and the coverage of existing stock.

Decision route for this supply case

  1. Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
  2. Assess restart timing, available batches, qualified sources and a lawful bridging stock separately.
  3. Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.

Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.

Request a structured supply review →

Operational shortage resilience: GDP warehousing and pharmaceutical storage

For manufacturing shortages, an agreed restart stock for Diclofenac Sandoz retard 100 mg - Filmtabletten can be received and distributed under control after release.

Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.

Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.

Operational checks for this notice

  • Match product identity using PZN 0792550, 0792544, active ingredient, strength, dosage form and pack.
  • Confirm the reported status and the period 29.05.2026 to 10.09.2026 with the primary source and potential suppliers.
  • Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
  • Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.

Relevant services and specialist pages

The following B2B topics are particularly relevant when handling a shortage involving Diclofenac Sandoz retard 100 mg - Filmtabletten:

Related topics